Latest Health News

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Alliance Aviation Services reported record flying hours and strong revenue growth in FY25, while statutory profit dipped slightly amid operational challenges.

Elixinol Wellness has launched its Healthy Chef Protein Water range, entering Australia’s rapidly expanding $499 million protein supplements market with a clean-label, functional beverage lineup.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

HomeCo Daily Needs REIT has announced a quarterly distribution of 2.125 cents per unit for Q2 2025, alongside confirmation of its Attribution Managed Investment Trust status for the fiscal year.

Vicinity Centres has reported a robust increase in revenue and net profit for FY25, alongside a steady distribution payout to securityholders. The company’s financial health shows promising resilience amid a competitive real estate market.

Neurizon Therapeutics reports encouraging topline results from its Phase 1 Open-Label Extension study of NUZ-001, demonstrating long-term safety and a significant survival advantage in ALS patients. These findings pave the way for the pivotal HEALEY ALS Platform Trial planned for late 2025.

Perpetual Limited is set to record a significant $153.7 million non-cash impairment for FY25, largely driven by challenges in its J O Hambro boutique. This move underscores ongoing asset outflows but leaves liquidity intact.

Magellan Financial Group has announced a fully franked total dividend of AUD 0.469 per share, combining a final dividend, a performance fee dividend, and a special dividend for the six months ending June 2025.

The Lottery Corporation Limited has announced a fully franked ordinary dividend of AUD 0.085 per share for the first half of FY2025, accompanied by a Dividend Reinvestment Plan available to Australian and New Zealand shareholders.

Pharmx Technologies Limited reported a 13% increase in revenue for FY25, driven by expanded supplier-pharmacy connections and Marketplace platform growth, while profit before tax declined due to significant investments in new technology platforms.

MLG Oz Limited reported a 15.5% increase in revenue to $548.3 million and a 10.7% rise in net profit after tax to $12.1 million for FY2025, driven by new contract wins and improved margins in the second half. Despite strong financials, the company declared no dividend for the year.